Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-251-4400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$77.47 million
Profitability
Miscellaneous
Employees198
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions
What is Heron Therapeutics' stock symbol?
Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."
How were Heron Therapeutics' earnings last quarter?
Heron Therapeutics Inc (NASDAQ:HRTX) released its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.30. The biotechnology company earned $31.60 million during the quarter, compared to analyst estimates of $28.04 million. Heron Therapeutics had a negative net margin of 194.43% and a negative return on equity of 49.22%. The business's revenue was up 172.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.09) earnings per share. View Heron Therapeutics' Earnings History.
When is Heron Therapeutics' next earnings date?
What price target have analysts set for HRTX?
9 equities research analysts have issued 1-year target prices for Heron Therapeutics' shares. Their forecasts range from $38.00 to $80.00. On average, they expect Heron Therapeutics' stock price to reach $53.1111 in the next twelve months. This suggests a possible upside of 191.3% from the stock's current price. View Analyst Price Targets for Heron Therapeutics.
What is the consensus analysts' recommendation for Heron Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heron Therapeutics.
What are Wall Street analysts saying about Heron Therapeutics stock?
Here are some recent quotes from research analysts about Heron Therapeutics stock:
- 1. Cowen Inc analysts commented, ": Post 1Q19, we are reiterating our Overweight rating and $18 PT on CHMA. We believe the stock continues to trade at a significant discount to its potential intrinsic value. We believe the risk-reward going into Phase 3 data for Mycapssa (oral octreotide) for the treatment of acromegaly, to be released in 3Q19, remains positive. As the company advances Mycapssa toward approval, we expect data readouts, approvals, and upward earnings revisions to drive CHMA’s stock higher." (5/9/2019)
- 2. Northland Securities analysts commented, "We anticipate the Company will submit a briefing package to the FDA and request a ‘Type A’ meeting to clarify issues cited in the Complete Response Letter (CRL) received on April 30, 2019 relating to the NDA for HTX-011 (bupivacaine ER, plus meloxicam ER) for the treatment of post-operative pain management. The CRL requested additional Controls (CMC) and non-clinical information deemed necessary for HTX-011’s approval. We anticipate a Type A meeting will be held late-June/early-July, with minutes available within 30 days of its occurrence. We anticipate the minutes will clarify a path forward for resubmission of the NDA for HTX-011." (5/9/2019)
- 3. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (5/9/2019)
- 4. Stifel Nicolaus analysts commented, "We are certainly disappointed in the CRL for HTX-011, there is no doubt about that, but we would be buying today’s weakness as we continue to believe HTX-011 will be approved. The FDA flagged CMC and non-clinical issues and it is a bit hard to know, at this time, exactly when the company will be able to re-file its NDA until HRTX meets with the FDA. With that said, we remain confident in HTX-011’s approvability given its robust Phase 2/3 dataset, opioid sparing capability and the fact the FDA is not requiring any additional clinical work, which we view as a good sign. With the stock trading around ~$18, we think this is a significant buying opportunity for long-term investors given HTX-011’s product profile and the size of the commercial opportunity. We lower our target price to $38 to reflect a delayed HTX-011 approval and launch. Reiterate Buy." (5/1/2019)
- 5. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and expect upward earnings revisions, along with an approval of HTX-011, to drive HRTX shares higher. We expect upside to come from Cinvanti and HTX-011. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $50." (12/31/2018)
Has Heron Therapeutics been receiving favorable news coverage?
News coverage about HRTX stock has been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Heron Therapeutics earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the company's share price in the next several days. View News Stories for Heron Therapeutics.
Who are some of Heron Therapeutics' key competitors?
Some companies that are related to Heron Therapeutics include Ascendis Pharma A/S (ASND), Beigene (BGNE), Marina Biotech (MRNA), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), FibroGen (FGEN), ACADIA Pharmaceuticals (ACAD), Mirati Therapeutics (MRTX), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), United Therapeutics (UTHR), Uniqure (QURE) and Global Blood Therapeutics (GBT).
What other stocks do shareholders of Heron Therapeutics own?
Who are Heron Therapeutics' key executives?
Heron Therapeutics' management team includes the folowing people:
- Dr. Barry D. Quart, Pres, CEO & Director (Age 62)
- Mr. Robert E. Hoffman C.P.A., CPA, CFO & Sr. VP of Fin. (Age 53)
- Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 59)
- Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 45)
- Mr. Sean T. Ristine, VP of HR (Age 49)
Who are Heron Therapeutics' major shareholders?
Heron Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (10.70%), Janus Henderson Group PLC (6.65%), Clearbridge Investments LLC (2.75%), FIL Ltd (2.26%), Eagle Asset Management Inc. (2.13%) and Rubric Capital Management LP (1.89%). Company insiders that own Heron Therapeutics stock include Barry D Quart, John Poyhonen, Kevin C Tang, Kimberly Manhard, Robert Hoffman, Robert Rosen and Waage Christian. View Institutional Ownership Trends for Heron Therapeutics.
Which institutional investors are selling Heron Therapeutics stock?
HRTX stock was sold by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, FIL Ltd, Janus Henderson Group PLC, Bank of Montreal Can, Rothschild & Co. Asset Management US Inc., Oppenheimer & Co. Inc., Marshall Wace North America L.P. and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Heron Therapeutics company stock in the last year include Barry D Quart, Kevin C Tang, Kimberly Manhard, Robert Hoffman and Robert Rosen. View Insider Buying and Selling for Heron Therapeutics.
Which institutional investors are buying Heron Therapeutics stock?
HRTX stock was bought by a variety of institutional investors in the last quarter, including Clearbridge Investments LLC, JPMorgan Chase & Co., WS Management Lllp, FMR LLC, Rosenblum Silverman Sutton S F Inc. CA, Oak Ridge Investments LLC, Candriam Luxembourg S.C.A. and C WorldWide Group Holding A S. Company insiders that have bought Heron Therapeutics stock in the last two years include John Poyhonen, Kevin C Tang and Waage Christian. View Insider Buying and Selling for Heron Therapeutics.
How do I buy shares of Heron Therapeutics?
Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Heron Therapeutics' stock price today?
One share of HRTX stock can currently be purchased for approximately $18.23.
How big of a company is Heron Therapeutics?
Heron Therapeutics has a market capitalization of $1.44 billion and generates $77.47 million in revenue each year. The biotechnology company earns $-178,840,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Heron Therapeutics employs 198 workers across the globe.View Additional Information About Heron Therapeutics.
What is Heron Therapeutics' official website?
How can I contact Heron Therapeutics?
Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]
MarketBeat Community Rating for Heron Therapeutics (NASDAQ HRTX)
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe HRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
